About 15 million euros invested, more than 1,050 square meters, 30 percent of spaces upgraded.
Ribbon cutting took place in the presence of Governor Marsilio
The acquisition process, already announced last August, was completed on schedule and marks the beginning of the integration process of the two companies.
Alfasigma steadies its leadership in the gastrointestinal area and in the research on microbiota by aiming to expand its presence in the international market.
In alignment with our strategic development plan, we are pleased to announce that the new subsidiary Alfasigma Deutschland GmbH with headquarter in Munich is operative, starting from 1st October 2022.
Gastrointestinal therapeutics are our specialty. Everyday we strive to give a concrete answer to functional gastro-intestinal disorders, gastro-oesophageal reflux disorder, hepatic encephalopathy and chronic liver disease (cirrhosis).
Vascular investigation is a company corporate mission. Venous diseases, lower extremity artery disease, diabetic microangiopathies and ventricular arrhythmia are the main pathologies in which we offer solutions.
In the metabolic area, our R&D has developed Carnitine, an amino acid derivative whose insufficiency can impair the metabolism of essential tissues, such as those of the heart and muscles.
With our supplements, we are responding to the demand for a vast range of elements aimed at neural tissue well-being, recovery of muscle tone and combating physical and mental fatigue.
doctorAsyou provides physicians and researchers with easier and smarter access to the most relevant EBM (Evidence Based Medicine) topics.
The doctorAsyou search engine is updated daily and returns over 30 million abstracts, combining the three most authoritative databases in the world: Pubmed, ICRTP, Clinicaltrials.gov
lf you're searching for a scientific article, a paper, an abstract or more, try to use it directly from this search bar.
You’re entering Alfasigma global website
I agree